Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)

Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC, Cuppen I, van den Berg LH, van der Pol WL.
BMJ Open. 2018. 30;8(7):e019932. 
Protocol of the “SPACE” in wich MFM is used as an outcome measure.

PubMed link

Keywords: Cross-over, Fatigability, Neuromuscular junction, Pyridostigmine, Spinal Muscular Atrophy

Articles in scientific journals